Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER-Medicare analysis.
about
High incidence of ischemic stroke occurrence in irradiated lung cancer patients: a population-based surgical cohort study.Pulmonologist involvement, stage-specific treatment, and survival in adults with non-small cell lung cancer and chronic obstructive pulmonary disease.Disparate survival trends in histologic subtypes of metastatic non-small cell lung cancer: a population-based analysisHyperlipidemia and statins use for the risk of new-onset anxiety/depression in patients with head and neck cancer: A population-based study.Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005.Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak TrialsSurvival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities.Treatment patterns and cost-effectiveness of first line treatment of advanced non-squamous non-small cell lung cancer in Medicare patients.Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?Irradiation enhanced risks of hospitalised pneumonopathy in lung cancer patients: a population-based surgical cohort studySurvival Prediction in Ambulatory Patients With Stage III/IV Non-Small Cell Lung Cancer Using the Palliative Performance Scale, ECOG, and Lung Cancer Symptom Scale.Darkness before dawn, but will the sun always rise?Survival after recurrence of stage I-III breast, colorectal, or lung cancer.
P2860
Q35141687-8F079BDE-E2AD-4378-A90C-E2E9BE35417FQ35565178-80A10B42-12E7-4D15-A912-CDE25AF6A695Q35993134-70CF8997-6231-4EA3-BF6D-FB4B6D11D9FBQ36330244-3837B695-9148-4F4E-9E3E-C2A8BB082884Q36447510-AA70606B-1BAA-4077-9433-8208E2BAEC3EQ37242517-87BBD6FE-25E3-4A10-96D0-C4F4DF9895FFQ40315977-C81E81B6-E6EA-4E22-B7A5-56302264747AQ40602351-271EF765-C974-4962-A5CB-9E35A8AF1224Q41043819-8725CEEE-BC3F-48E0-B156-8E9DA58245F0Q42267544-4DC6D997-E136-478D-8B34-03C9DDF99491Q43761150-83E78A58-E061-4509-98FE-42E29F547958Q46935443-B8026C65-3498-4F0C-8E2C-7688992041B2Q50528546-4562F365-5449-4EDD-946D-A19076A5D6CF
P2860
Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER-Medicare analysis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Real-world effectiveness of sy ...... cer: a SEER-Medicare analysis.
@en
type
label
Real-world effectiveness of sy ...... cer: a SEER-Medicare analysis.
@en
prefLabel
Real-world effectiveness of sy ...... cer: a SEER-Medicare analysis.
@en
P2093
P2860
P1433
P1476
Real-world effectiveness of sy ...... ncer: a SEER-Medicare analysis
@en
P2093
Camille Ragin
Fadlo R Khuri
Madhusmita Behera
Nabil F Saba
Rebecca Pentz
Sungjin Kim
Suresh S Ramalingam
Taofeek K Owonikoko
Zhengjia Chen
P2860
P304
P356
10.1634/THEONCOLOGIST.2012-0480
P577
2013-05-01T00:00:00Z